+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review



17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review



Maturitas 81(1): 28-35



Several formulations combining estrogens and progestins for hormone therapy (HT) have been approved worldwide for the treatment of menopausal symptoms, yet recent data indicate a decline in their use and an increase in compounded bioidentical HT. Up to now, no single product combining natural 17β-estradiol and progesterone has been approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA). A phase 3 trial (REPLENISH) is underway to study a novel oral formulation of solubilized 17β-estradiol and natural progesterone combined in a single gelatin capsule (TX-001HR; TherapeuticsMD, Inc, Boca Raton, FL) for treating vasomotor symptoms (VMS) in postmenopausal women. The REPLENISH trial evaluates the efficacy and safety of TX-001HR (4 doses) versus placebo for the reduction of moderate to severe VMS frequency and severity at 4 and 12 weeks and evaluates the endometrial safety of the combinations at 1 year. TX-001HR contains hormones that are molecularly identical to endogenous estradiol and progesterone and is intended as an option for women who prefer bioidentical hormones; further, it does not contain peanut oil, a common allergen. The constituents of TX-001HR, in a pharmacokinetic report, showed similar bioavailability and safety compared with reference estradiol tablets and micronized progesterone capsules administered together. Published data suggest a safer profile of estradiol and natural progesterone compared with HT containing conjugated equine estrogens and progestins. This report summarizes the methodology of the REPLENISH trial and reviews the evidence suggesting clinical differences between HT containing progesterone or progestins, and estradiol or conjugated equine estrogens.

(PDF emailed within 0-6 h: $19.90)

Accession: 057009970

Download citation: RISBibTeXText

PMID: 25835751

DOI: 10.1016/j.maturitas.2015.02.266


Related references

Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy. Menopause 22(12): 1308-1316, 2016

Amenorrhea during menopausal hormone replacement therapy with a percutaneous estradiol and oral micronized progesterone combination. Contraception, Fertilite, Sexualite 21(11): 849-852, 1993

Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal. Climacteric 20(4): 331-338, 2017

Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstetrics & Gynecology 73(43): 606-612, 1989

Evidence on the use of progesterone in menopausal hormone therapy. Climacteric 1-9, 2018

Hormone replacement therapy with transdermal estradiol gel and oral progesterone: Effects on menopausal symptoms and lipid metabolism. Wiener Klinische Wochenschrift 112(14): 629-633, 28 Juli, 2000

Hormone replacement therapy with a transdermal estradiol gel and oral micronized progesterone. Effect on menopausal symptoms and lipid metabolism. Wiener Klinische Wochenschrift 112(14): 629-633, 2000

The effect of ethinyl estradiol administration during the follicular phase of the menstrual cycle on luteinizing hormone follicle stimulating hormone progesterone and estradiol levels in the subsequent luteal phase. Journal of Clinical Endocrinology & Metabolism 39(3): 465-470, 1974

Progesterone or progestin as menopausal ovarian hormone therapy: recent physiology-based clinical evidence. Current Opinion in Endocrinology, Diabetes, and Obesity 22(6): 495-501, 2016

The endometrial and breast safety of menopausal hormone therapy containing micronised progesterone: A short review. Australian & New Zealand Journal of Obstetrics & Gynaecology 57(1): 12-15, 2017

Combination of the three sex hormones, estradiol, progesterone and testosterone, in the treatment of menopausal disorders. La Presse Medicale 61(18): 365-366, 1953

Serum luteinizing hormone follicle stimulating hormone estradiol progesterone and testosterone levels in post menopausal women with and without endometrial cancer. Cancer Treatment Reports: 1207, 1979

The menopausal transition analysis of luteinizing hormone follicle stimulating hormone estradiol and progesterone concentrations during menstrual cycles of older women. Journal of Clinical Endocrinology & Metabolism 42(4): 629-636, 1976

The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation with progesterone or progesterone and estradiol. Fertility and Sterility 87(3): 504-508, 2006

Combination of substitute hormone therapy with natural metabolites glycine and limontar in the tretament of the menopausal syndrome. Problemy Endokrinologii 45(4): 19-24, 1999